Kelani assumed his role in 2019. In December 2025, EIPICO oversaw the launch of ADALIMAB, the first biologicals and biosimilars product from its EIPICO 3 factory, after the Egyptian Drug Authority and Industrial Development Authority granted an operation license. It also established the Arab Company for Active Pharmaceutical Ingredients (Arab API), in which it has a 33% stake. Revenue in 2025 reached $195 million, growing 26% YoY. In April 2026, ARAB API explored a partnership with PETROJET for its 96,000 square-meter multi-purpose facility, targeting a capacity of 750 tons of APIs and 500 tons of intermediates.